Literature DB >> 14600787

Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.

Nurşen Düzgün1, Ergin Ayaşlioğlu, Hüseyin Tutkak, Olcay T Aydintuğ.   

Abstract

Serum levels of proinflammatory cytokines, interleukin-1 beta (IL-1beta), tumor necrosis factor alpha, (TNF-alpha), and their inhibitors, IL-1 receptor antagonist (IL-1ra) and soluble TNF receptor 1 (sTNFR1), were determined by enzyme-linked immunosorbent assay in 104 patients with Behçet's disease (65 active, 39 inactive) and 40 healthy controls. The levels of IL-1beta and IL-1ra were significantly higher in both active and inactive patients than in control subjects (P<0.01 and P< 0.01, respectively). The concentrations of TNF-alpha and sTNFR1 were found to be higher in active patients than in controls (P< 0.01 and P< 0.001, respectively). There were no significant differences in the serum levels of these cytokines and their inhibitors between active and inactive patients. Significant increases in mean C-reactive protein level and erythrocyte sedimentation rate were found in patients with active vs inactive disease (P< 0.001 and P< 0.05, respectively). C-reactive protein values correlated with erythrocyte sedimentation rate but not with cytokines or their inhibitors. Our conclusion is that elevated serum TNF-alpha and sTNFR1 seem to be important inflammatory mediators in Behcet's disease. The statistically significant increase in these levels may arise from the severity of inflammation in the tissue or organ involved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600787     DOI: 10.1007/s00296-003-0400-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  26 in total

Review 1.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

2.  Role of gammadelta T lymphocytes in the development of Behçet's disease.

Authors:  N Yamashita; H Kaneoka; S Kaneko; M Takeno; K Oneda; H Koizumi; M Kogure; G Inaba; T Sakane
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

Review 3.  Interleukin-1 and interleukin-1 receptor antagonist.

Authors:  C A Dinarello
Journal:  Nutrition       Date:  1995 Sep-Oct       Impact factor: 4.008

4.  Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis.

Authors:  M Rooney; H Varsani; K Martin; P R Lombard; J M Dayer; P Woo
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

5.  Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity.

Authors:  B Turan; H Gallati; H Erdi; A Gürler; B A Michel; P M Villiger
Journal:  J Rheumatol       Date:  1997-01       Impact factor: 4.666

6.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

7.  [Soluble receptors of TNF-alpha in rheumatoid arthritis].

Authors:  E L Nasonov; N V Chichasova; M Iu Samsonov; G P Tilz; E L Nikiforova; O V Stepanets; M B Nasonova; D Fuks
Journal:  Klin Med (Mosk)       Date:  2001

8.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis.

Authors:  G S Firestein; D L Boyle; C Yu; M M Paine; T D Whisenand; N J Zvaifler; W P Arend
Journal:  Arthritis Rheum       Date:  1994-05

9.  Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity.

Authors:  G Yosipovitch; B Shohat; J Bshara; A Wysenbeek; A Weinberger
Journal:  Isr J Med Sci       Date:  1995-06

10.  Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Authors:  Cem Evereklioglu; Hamdi Er; Yusuf Türköz; Mustafa Cekmen
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

View more
  20 in total

1.  [Interleukin-1 cytokines, inflammasomes, NOD-signalosomes and autoinflammation].

Authors:  S D Gadola
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

Review 2.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

3.  Peripheral arterial disease in patients with Behçet's disease.

Authors:  Ilknur Balta; Sevket Balta; Sait Demirkol; Ozlem Ekiz
Journal:  Rheumatol Int       Date:  2013-03-28       Impact factor: 2.631

4.  Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet's disease.

Authors:  Suhail Aamar; Hagit Peleg; David Leibowitz; Tova Chajek-Shaul; Nurith Hiller; Samuel N Heyman
Journal:  Rheumatol Int       Date:  2013-02-15       Impact factor: 2.631

5.  LPS-stimulated production of TNF-alpha by peripheral blood monocytes in patients with Behcet's disease.

Authors:  Gleb Slobodin; Yazeed Toukan; Itzhak Rosner; Michael Rozenbaum; Nina Boulman; Elsa Pavlotzky; Aharon Kessel; Elias Toubi
Journal:  Clin Rheumatol       Date:  2006-07-29       Impact factor: 2.980

Review 6.  Current and future treatments for Behçet's uveitis: road to remission.

Authors:  Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán
Journal:  Int Ophthalmol       Date:  2013-06-01       Impact factor: 2.031

7.  Anakinra treatment in drug-resistant Behcet's disease: a case series.

Authors:  Luca Cantarini; Antonio Vitale; Perla Scalini; Charles A Dinarello; Donato Rigante; Rossella Franceschini; Gabriele Simonini; Giulia Borsari; Francesco Caso; Orso Maria Lucherini; Bruno Frediani; Ilaria Bertoldi; Leonardo Punzi; Mauro Galeazzi; Rolando Cimaz
Journal:  Clin Rheumatol       Date:  2013-12-05       Impact factor: 2.980

8.  Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.

Authors:  Masamichi Kimura; Yoshihisa Tsuji; Masako Iwai; Masahiro Inagaki; Ali Madian; Takuya Yoshino; Minoru Matsuura; Hiroshi Nakase
Journal:  Intest Res       Date:  2015-04-27

Review 9.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

10.  Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist.

Authors:  Ming-Ling Tsai; Chi-Ting Horng; Show-Li Chen; Xiao Xiao; Chih-Hung Wang; Yeou-Ping Tsao
Journal:  Mol Vis       Date:  2009-08-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.